Risk factors and outcomes of delayed graft function in renal transplant recipients receiving a steroid sparing immunosuppression protocol

Figure 4 Three month and overall rejection free survival by induction agent and delayed graft function. Rejection free survival, censored for DSA+ in patients with alemtuzumab induction and PGF (C-PGF), alemtuzumab induction and DGF (C-DGF), IL2RA induction and PGF (IL2RA-PGF) and IL2RA induction and DGF (IL2RA-DGF) at A: 3 mo: 93.0%, 92.9%, 92.5% and 77.8% respectively, P = 0.03 and B: 5 year: 76.4%, 71.5%, 76.5% and 70.7%, P = 0.75. DGF: Delayed graft function; PGF: Primary graft function.